Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil.
Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil.
复制标题
吗替麦考酚酯治疗 4 周后，ABO 血型不相容的活体肾移植后的结果得到改善。
作者：
M. Mannami;N. Mitsuhata
abo血型不相容肾移植的超急性体液排斥反应限制了该手术的应用。我们评估了在以他克莫司作为主要免疫抑制剂的abo不相容活体肾移植前，用霉酚酸酯（MMF）（一种抑制B细胞产生抗体的化合物）治疗4周的效果。与未经MMF预处理的病例相比，我们未观察到18例接受MMF的患者中有任何由超急性体液排斥引起的移植物损失。总的来说，mmf治疗组和未治疗组的不良事件发生率相当。肾移植前4周给予MMF可有效抑制b细胞功能，提示MMF在预防体液性排斥反应中的潜在作用。
Hyperacute humoral rejection of ABO-incompatible kidney transplants limits the application of this procedure. We evaluated the effect of 4-week treatment with mycophenolate mofetil (MMF), a compound that inhibits antibody production by B cells, before ABO-incompatible living-donor kidney transplantation with tacrolimus as the primary immunosuppressant. In contrast with cases without MMF pretreatment, we did not observe any graft loss caused by hyperacute humoral rejection in the 18 patients who received MMF. Overall, the incidence of adverse events was comparable in the MMF-treated and -untreated groups. The administration of MMF 4 weeks before kidney transplant effectively inhibits B-cell function, suggesting a potential role for MMF in the prevention of humoral rejection.